Navigation Links
Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
Date:8/14/2014

patient Phase 2 study in cystic fibrosis (CF) subjects with chronic Pa lung infection. KaloBios has received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency for KB001-A for the treatment of Pa lung infection in CF patients. KB001-A has also received Fast Track Status from the U.S. FDA for the prevention of ventilator associated pneumonia. KaloBios is planning to seek a partner to help accelerate the development of this program.
  • KB004 is an anti-EphA3 mAb with potential in treating hematologic malignancies and solid tumors. KaloBios is running an ongoing Phase 1/2 study evaluating KB004 in hematologic malignancies. The Phase 1 dose escalation portion of that study in subjects with hematologic malignancies is fully enrolled with dosing ongoing. KaloBios initiated the Phase 2 expansion portion of the study focused on patients with certain EphA3 positive hematologic malignancies in 2014.
  • KB003 is an anti-GM-CSF mAb with potential to treat inflammatory diseases that was being developed for the treatment of severe asthma. In early 2014, KaloBios completed a Phase 2 clinical study in 160 patients with severe asthma which did not meet its primary endpoint of improvement in FEV1 from baseline as compared to placebo. As a result, KaloBios discontinued development of this compound in severe asthma, and is continuing to analyze the Phase 2 data to review with thought leaders. KaloBios is currently evaluating other possible indications in order to determine next steps, if any, in the development of KB003.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered®
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
    2. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
    3. Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
    4. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
    5. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
    6. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
    7. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
    8. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
    9. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
    10. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
    11. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... BOSTON , January 23, 2015 ... company, is delighted to announce that the Malcolm Campbell ... Miles Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions ...
    (Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
    (Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
    Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
    (Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
    (Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
    (Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
    (Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
    (Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
    Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
    ... Chase Cancer Center have discovered a new mechanism used by ... process is critical in preventing the development of cancersuggesting the ... underlying the disease. The findings will be published online ... The process investigated by Alfonso Bellacosa, M.D., Ph.D., Associate ...
    ... scientists to profile the entire genome of individual tumors ... best treatment for each patient,s particular type of cancer. ... the volume alone creates unique analytical problems. In ... BMC Medical Genomics , researchers from Huntsman Cancer ...
    ... News) -- The number of U.S. workers aged 16 and ... than half over the past two decades -- from 14 ... 2009, a new study reveals. "Although the prevalence of ... lead exposure are well characterized," researchers from the U.S. Centers ...
    ... Differences in male and female behaviour are often subject to ... better manual dexterity and are better at noticing things (like ... less time parking their cars and have less trouble than ... in which men tend to excel, are known as visuo-spatial ...
    ... (NLST) is the first scientific study that provides clear evidence ... lung cancer. NLST data shows 20 percent fewer lung cancer ... with the chest x-ray. Until now, no screening test for ... early, more treatable stage. Northwestern Memorial Hospital is the ...
    ... who watch adverts for unhealthy food on television are more likely ... by researchers in the Institute of Psychology, Health and Society examined ... to 13 years old from the North West of England. ... before being shown it again two weeks later. In each ...
    Cached Medicine News:Health News:Fox Chase researchers identify new mechanism used by cells to reverse silenced genes 2Health News:On-the-Job Lead Exposures Falling, But Still a Problem: CDC 2Health News:Sound localization at cocktail parties is easier for men 2Health News:CT scans unleash a breakthrough in catching early stage lung cancer 2Health News:TV food advertising increases children's preference for unhealthy foods 2
    ... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
    ... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
    ... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
    ... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
    Medicine Products: